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Tbjective: Bronchioloalveolar carcinoma is a clinically heterogeneous subtype of
on–small cell lung carcinoma that frequently has low 2-[18F]fluoro-D-glucose
FDG) uptake on positron emission tomographic scanning. We investigated whether
umor FDG avidity was associated with worse survival among patients with com-
letely resected node-negative pure and mixed bronchioloalveolar carcinoma.
ethods: We performed a cohort study of 36 patients who had completely resected
ure and mixed bronchioloalveolar carcinoma between 1998 and 2004, who had no
ilar or mediastinal lymph node metastases, and who had undergone a preoperative
ositron emission tomographic scan. Tumor FDG avidity was defined as a stan-
ardized uptake value of 2.5 or greater. Survival analysis was performed with a
roportional hazards model.
esults: Of 36 patients studied, 26 patients (72%) were alive and 10 patients (28%)
ere dead after a median follow-up of 31 months (interquartile range 17-41months).
eventeen patients (47%) had FDG-avid tumors, and 19 patients (53%) had non-
vid tumors. Three-year survival was 49% in the FDG-avid group and 95% in the
on-avid group (P  .005). FDG avidity had a hazard ratio of death of 8.6 (95%
onfidence interval 1.4-244.7, P  .02) after adjusting for tumor size, the presence
f multifocal bronchioloalveolar carcinoma, and the presence of histologically
ixed bronchioloalveolar carcinoma.
onclusions: Preoperative tumor FDG standardized uptake value of 2.5 or greater
n positron emission tomography is a powerful predictor of long-term mortality in
atients with lymph node–negative pure and mixed bronchioloalveolar carcinoma
ho undergo complete surgical resection. Patients with a high level of FDG uptake
standardized uptake value 2.5) may benefit from adjuvant chemotherapy or more
requent clinical follow-up.
ronchioloalveolar carcinoma (BAC) is classified as a subset of lung adeno-
carcinoma but has a distinct clinical presentation, tumor biology, response
to therapy, and prognosis from other subtypes of non–small cell lung
arcinoma (NSCLC).1-4 BAC histology is most commonly found in small lesions
dentified incidentally on chest radiography or computed tomographic (CT) scan and
ay represent a precursor lesion to invasive adenocarcinoma.5,6 The 1999 World
ealth Organization criteria for diagnosis of BAC require the absence of stromal,
ascular, and pleural invasion. Tumors with invasive features and BAC are cate-
orized as adenocarcinoma with mixed features (mixed BAC). Whereas pure BAC
ccounts for about 4% of NSCLC, tumors with histologically mixed BAC and
denocarcinoma may account for 20% of all NSCLC, and the incidence of BAC
he Journal of Thoracic and Cardiovascular Surgery ● Volume 132, Number 5 1189
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TSay be rising.7-9 Stage for stage, patients with pure and
ixed BAC have a higher rate of long-term survival than
atients with pure adenocarcinoma.3,5,10
Positron emission tomography (PET) with fluoro-2-deoxy-
-glucose (FDG) is a highly sensitive imaging modality to
ifferentiate benign from malignant lung nodules and to
etect the presence of mediastinal lymph node and distant
etastases.11 A standardized uptake value (SUV) above 10
as been associated with more advanced stage and increased
ortality among patients with NSCLC.12-16 While approx-
mately 85% of NSCLCs are FDG avid, only 50% to 60%
f tumors with BAC histology are FDG avid, when FDG
vidity is defined as an SUV of 2.5 or greater.17,18 Another
tudy found that pure BAC was more likely to be undetect-
ble with PET and multifocal BAC was more likely to be
etectable with PET.19 Lower metabolic activity in tumors
ith BAC histology is presumed to be secondary to the
lower rate of proliferation of BAC compared to other lung
ancers. If a higher metabolic activity is associated with
ore aggressive tumor biology, FDG avidity might identify
group of patients more likely to have a recurrence and die
f disease. These patients might be more likely to benefit
rom adjuvant chemotherapy or closer clinical surveillance.
We investigated whether preoperative tumor FDG avid-
ty predicted long-term mortality in patients with early-stage
ung cancer with pure BAC and mixed BAC adenocarci-
oma. Since lymph node involvement is a powerful predic-
or of poor survival in patients with lung cancer, we re-
tricted our study to patients without evidence of hilar and
ediastinal lymph node metastases.
atients and Methods
rom 1998 to 2004, 76 patients who underwent lung cancer
esection at our institution had BAC features on final pathologic
xamination. Specimens without stromal, pleural, or vascular in-
asion were classified as pure BAC, while specimens with BAC
istology and any invasive features were classified as adenocarci-
oma with mixed features (mixed BAC). All specimens were
eviewed by surgical pathologists at the University of California,
an Francisco, after resection; however, specimens were not re-
Abbreviations and Acronyms
BAC  bronchioloalveolar carcinoma
CI  confidence interval
CT  computed tomography
FDG  fluoro-2-deoxy-D-glucose
HR  hazard ratio
IQR  interquartile range
NSCLC non–small cell lung carcinoma
PET  positron emission tomography
SUV  standardized uptake valueeviewed for this study. One patient died within 30 days of the t
190 The Journal of Thoracic and Cardiovascular Surgery ● Novperation and was excluded. Of the 75 remaining patients (Figure 1),
e excluded from the study 4 patients with N1 only disease, 5 with
2 disease, 1 with T3 disease, 4 with unresectable or metastatic
isease, and 1 patient who underwent wedge resection and did not
ave hilar or mediastinal nodal sampling. Patients with mediastinal
DG uptake who underwent neoadjuvant chemotherapy were con-
idered to have N2 disease regardless of final pathologic stage and
ere excluded from the study. Of the 61 eligible patients, 40
66%) underwent a preoperative PET scan. Five patients did not
ndergo preoperative PET scanning because mediastinoscopy
lone was used for staging, and 3 patients did not undergo PET
canning because of subcentimeter tumors unlikely to be detected
y PET scan. PET scanning only became routinely integrated into
ur clinical practice in 2001. Eleven of 13 patients with BAC who
ere operated on before 2001 did not undergo preoperative PET
canning.
Patients were administered an average of 14 mCi of FDG and
maged 60 minutes later with a CTI HR PET scanner (CTI PET
ystems, Inc, Knoxville, Tenn.). Images were reconstructed with
rdered subjects expectation maximization algorithm in two sub-
ets with eight iterations. PET scanning was performed either at
ur institution or at satellite facilities. Maximum tumor SUV was
ecorded for each of the patients. Elevated FDG uptake was
onsidered to be an SUV of 2.5 or more. This threshold is used at
ur institution for differentiating malignant from benign lung
odules when NSCLC is suspected and is a common threshold
sed in the literature.14,17,18,20 Four patients who underwent PET
canning at satellite facilities were excluded because maximum
umor SUV was not reported.
Four patients with completely resected multifocal BAC were
ncluded in this study. Three patients had more than one tumor in
he same lobe of the lung and underwent lobectomy. One patient
ad two wedge resections, one from each lung, including hilar and
ediastinal node sampling. In patients with multifocal BAC the
argest SUV was used in the analysis. Thirty patients (83%)
nderwent lobectomy, 1 (3%) underwent pneumonectomy, and 5
14%) underwent wedge resection or segmentectomy alone. Three
atients (8%) were treated with neoadjuvant chemotherapy. Two
atients were treated as part of a clinical trial of neoadjuvant
hemotherapy for stage I and II lung cancer, and 1 patient with
ultifocal BAC (one in each lung) was treated with chemotherapy
etween resections. Prechemotherapy PET scan results were used
n 2 of these patients. In 1 patient only a postchemotherapy PET
can was documented. As previously mentioned, patients with
DG-avid mediastinal nodes who received neoadjuvant chemo-
herapy were considered to have N2 disease and were excluded
rom the study. Two patients (5%) were treated with adjuvant
hemotherapy for stage Ib disease.
All patients included in this study underwent preoperative chest
T scan with either 3- or 5-mm sections. The presence of ground-
lass opacity and focal consolidation in or surrounding the tumor
as recorded.
The Social Security Death Index was used to determine vital
tatus and date of death. Follow-up time was defined as the number
f months between the date of operation and the date of death or
he date of data analysis for living patients.
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TStatistical Analysis
linical characteristics of patients with an SUV of 2.5 or more and
n SUV of less than 2.5 were compared. All statistical analysis was
erformed with STATA release 9.1. Categorical variables were
ompared by the Pearson 2 test or the Fisher exact test. Contin-
ous variables were compared by the Student t test or the Mann-
hitney rank sum test. Survival between FDG-avid and non-avid
roups was compared by a proportional hazards model. P values
nd confidence intervals (CIs) for variables in the model were
alculated by likelihood ratio testing. Each variable in the model
as sequentially dropped to assess for confounding by noting
hanges in the hazard coefficient and P value with exclusion of a
ariable. The presence of multifocal BAC and mixed BAC were
ncluded in the model for face validity. Interactions were tested for
y adding variable cross-product terms to the model.
thical Considerations
his research study involved analysis of existing data from the
niversity of California, San Francisco, Thoracic Oncology clin-
cal database with no subject intervention. This study was ap-
roved by the University of California San Francisco Institutional
Lung resection wi
1998-
N=
Eligible for study
N=61
(81%)
Operation before 2001
N=11
PET Scan documented 
N=36
(59%)
Adequate PE
Locally 
Tum
Figure 1. Flow diagram of patient selection for this
emission tomography.eview Board (approval number H8714-11647-10). i
The Journal of Thoracicesults
f the 36 patients studied, 26 patients (72%) were alive and
0 patients (28%) were dead after a median follow-up of 31
onths (interquartile ratio [IQR] 17-41 months). The me-
ian tumor SUV was 2.2 (IQR 1.4-4.5). The distribution of
umor SUV and tumor size in patients alive and dead at last
ollow-up are graphically displayed in Figure 2. Seventeen
atients (47%) had FDG-avid tumors, and 19 patients (53%)
ad non-avid tumors. Clinical characteristics of both groups
f patients are summarized in Table 1. Mean age, proportion
f women and Asians, and smoking status were similar in
oth groups. There was also no significant difference in the
ercentage of patients in either group who had ground-glass
pacities or focal consolidation on CT scan. Patients with
round-glass opacities had a lower mean tumor SUV than
atients without such opacities (1.8 vs 3.2), but this differ-
nce did not reach statistical significance (P  .16). No
atient in this study had complete ground-glass opacities.
Operative procedure and histopathologic characteristics
re summarized in Table 2. Of note, tumor size was signif-
AC histology
4
ot eligible for study
N=14
(19%)
an not documented
=25
1%)
Mediastinoscopy for staging
N=5
nced disease
1
N1 or N2 disease
N=9
Unresectable or metastatic
N=4
Other reason
N=6
cm 
y. BAC, bronchioloalveolar carcinoma; PET, positronth B
200
75
N
T sc
N
(4
adva
N=
or <1
N=3
studcantly larger in the FDG-avid group (3.4 vs 2.8 cm), P 
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G
TS05. The percentage of patients with adenocarcinoma with
AC features (mixed BAC) was not significantly different
etween groups, with 71% among patients with an SUV of
.5 or larger compared with 53% among patients with an
UV less than 2.5, P  .27. The number of patients with
ultifocal BAC was also similar between groups, with 2
atients (12%) among patients with an SUV of 2.5 or larger
ompared with 1 patient (5%) among patients with an SUV
f less than 2.5, P  .59.
1
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tu
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tumor SUV
Alive Dead
Distribution of SUV by tumor size
igure 2. Distribution of maximum tumor standardized uptake
alue (SUV) among patients with early-stage bronchioloalveolar
arcinoma (BAC). Points represent patients who are labeled as
ither alive or dead at follow-up. Length of follow-up time was
ariable among patients. PET, positron emision tomography.
ABLE 1. Patient characteristics stratified by FDG avidity
SUV < 2.5
(n  19)
SUV > 2.5
(n  17) P value*
ge, y (mean  SD) 70.0 8.3 71.8  9.0 .53
emale, n (%) 11 (58%) 11 (65%) .68
thnicity
Non-Asian 16 (76%) 18 (95%)
Asian 5 (26%) 1 (6%) .18
moking status
Current 1 (5%) 0
Past 12 (63%) 14 (82%)
Never 6 (32%) 3 (18%) .35
T scan findings†
Ground-glass opacity 4 (21%) 3 (18%) .57
Consolidation 1 (5%) 4 (24%) .14
DG, Fluoro-2-deoxy-D-glucose; SUV, standardized uptake value; SD, stan-
ard deviation; CT, computed tomographic. *P value is for t test for age
nd Fisher exact test for all other comparisons. †Partial ground glassmpacity or focal lung consolidation on CT scan.
192 The Journal of Thoracic and Cardiovascular Surgery ● NovOverall, patients with FDG-avid and non-avid tumors
eceived similar treatment for their lung cancer (Table 2).
he proportion of patients treated with wedge resection was
imilar in both groups (P  .65). The proportion of patients
reated with neoadjuvant or adjuvant chemotherapy was
imilar in both groups (P  .80). Median follow-up time
as 33 months (IQR 22-41) among patients with an SUV of
ess than 2.5 and 20 months (IQR 16-39) among patients
ith an SUV of more than 2.5 (Table 2). Three-year sur-
ival was 95% for the FDG non-avid group and 49% for the
DG-avid group, P  .005 (Figure 3). When FDG avidity
nd mortality were analyzed alone in a proportional hazards
odel, the hazard ratio for SUV of 2.5 or more was 9.9 (CI
.2-79.4, P  .005).
When tumor size, multifocal BAC, and mixed BAC were
dded to the model, the adjusted hazard ratio was 8.6 (CI
.4-244.7, P  .02). When the proportional hazards model
as run excluding patients who received neoadjuvant or
djuvant chemotherapy, the hazard ratio for FDG-avid tu-
ors was 7.6, P  .04. Tumor size, multifocal BAC, and
ixed BAC histology were not significantly associated with
ncreased hazard of mortality in the multivariate model
Table 3) but were included because of existing evidence
hat these variables may predict worse long-term survival.
here were no significant interactions among variables
hen tested by adding variable cross-products into the
ABLE 2. Procedure, pathology, and outcome stratified by
DG avidity
SUV < 2.5
(n  19)
SUV > 2.5
(n  17)
P
value*
urgical procedure
Lobectomy or
pneumonectomy
17 (89%) 14 (82%) .65
Wedge resection or
segmentectomy
2 (11%) 3 (18%)
hemotherapy
Neoadjuvant 2 (11%) 1 (6%) .8
Adjuvant 1 (5%) 1 (6%)
istology
Pure BAC 9 (47%) 5 (29%) .27
Mixed BAC 10 (53%) 12 (71%)
Mucin-producing BAC 2 (11%) 1 (6%) .54
umor size, cm (median, IQR) 2.8 (1.8-3.5) 3.4 (2.6-4) .05
3 cm 9 (47%) 11 (65%)
3 cm 10 (53%) 6 (35%) .3
ultifocal tumor 1 (5%) 3 (18%) .33
edian follow-up time, mo (IQR) 33 (22-41) 20 (16-39) .57
DG, Fluoro-2-deoxy-D-glucose; SUV, standardized uptake value; BAC,
ronchioloalveolar carcinoma; IQR, interquartile range. *P value is for
ann-Whitney rank sum test for follow-up time and tumor size, and Fisher
xact test for histology, multifocal procedure, chemotherapy, and multifo-
al tumor comparisons.odel.
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G
TSiscussion
ur results suggest that preoperative tumor FDG avidity is
powerful predictor of long-term survival among patients
ho undergo resection of early-stage lung cancers with
AC histology. Although our study was small, patients with
AC histology and FDG-avid tumors on PET scan were more
ikely to die than patients with non-avid tumors, even after
djusting for tumor size, the presence of invasive features, and
ultifocal disease. Patient characteristics, such as age, female
ender, Asian ethnicity, and smoking status were similar
mong both groups, suggesting that these factors were un-
ikely to account for a significant amount of the effect seen.
oreover, patients in both groups were treated similarly.
oth groups had similar proportions of wedge resections or
egmentectomies, and both groups had similar proportions
f patients treated with adjuvant or neoadjuvant chemother-
py. Excluding the small group of patients who were treated
ith neoadjuvant or adjuvant chemotherapy did not change
he conclusions of the study.
Among patients undergoing surgical resection of early-
tage lung cancer, mediastinal lymph node metastases and,
o a lesser extent, hilar lymph node metastases are powerful
redictors of long-term mortality. PET scanning is increas-
ngly used to evaluate for mediastinal and distant metastatic
isease as part of clinical lung cancer staging. High-intensity
umor SUV, varying between 7 and 10 depending on the
tudy, has consistently been associated with advanced-stage
ung cancer and poor prognosis among patients with surgi-
ally resected lung cancer.11-14,20
Unlike other subsets of NSCLC, PET scanning is not a
igure 3. Kaplan-Meier curves of patients with early-stage bron-
hioloalveolar carcinoma (BAC), stratified by fluoro-2-deoxy-D-
lucose (FDG) avidity. P value given is calculated by the log-rank
est. SUV, standardized uptake value.seful diagnostic test to differentiate between a benign f
The Journal of Thoraciculmonary process and BAC since only approximately 50%
f patients with BAC have FDG-avid tumors on PET scan.
ur results demonstrate that among patients with lymph
ode–negative NSCLC with BAC features on histologic
xamination, the presence of tumor FDG uptake, defined as
maximum SUV of 2.5 or more, is useful in identifying a
opulation at high risk for mortality. Patients at high risk for
ortality might benefit from adjuvant cytotoxic chemother-
py or treatment with an epidermal growth factor receptor
yrosine kinase inhibitor. Conversely, patients with non-
vid tumors, who in this study had a remarkable 95% 3-year
urvival, seem unlikely to benefit from adjuvant chemother-
py. Furthermore, this subset of patients might be ade-
uately treated with a limited lung resection. The benefit of
djuvant chemotherapy in high-risk BAC group patients can
nly be determined by prospective trials or by analyzing the
ffect of adjuvant chemotherapy on mortality among exist-
ng adjuvant chemotherapy data in subsets of patients with
AC who have preoperative PET scan data.
In this study, we included patients with both pure and
ixed BAC. Evidence strongly supports the prognostic
alue of any BAC features on histologic examination com-
ared with pure adenocarcinoma. Although several Japa-
ese investigators have described improved survival with
ure BAC compared with mixed BAC, this finding has not
een reproduced in Western institutions.10,21-25 In addition,
he molecular biology of both pure and mixed BAC is
istinct from pure adenocarcinoma, supporting the unique
iological behavior of tumors with mixed BAC histology.26
limitation of this study, and any study including mixed
AC, is that a standardized classification scheme for mixed
AC that is reflective of prognosis does not exist. While
nly patients classified as having pure BAC meet the World
ealth Organization criteria for BAC, we included patients
ith mixed BAC in our study because they comprise a large
roportion of patients with early-stage lung cancer and have
imilar PET characteristics to pure BAC. In this study,
umor FDG avidity remained a powerful predictor of mor-
ality even after adjusting for the presence of invasive
ABLE 3. Proportional hazards model of the association
etween FDG avidity and mortality
HR 95% CI P value*
UV  2.5 8.6 (1.4-244.7) .02
umor size in cm 1.2 (0.8-1.6) .39
ultifocal tumor 0.4 (0.04-4.2) .39
ure BAC 1.3 (0.3-6.1) .71
DG, Fluoro-2-deoxy-D-glucose; HR, hazard ratio; CI, confidence interval;
UV, standardized uptake value; BAC, bronchioloalveolar carcinoma.
P values and 95% confidence intervals were calculated with likelihood
atio testing.eatures in multivariate analysis.
and Cardiovascular Surgery ● Volume 132, Number 5 1193
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G
TSPatients with BAC are a clinically heterogeneous group,
nd we used multivariate analysis to adjust for the presence
f invasive features and the presence of multifocal lung
ancer. Even after adjustment for these variables, FDG
vidity remained a powerful predictor of mortality. Three
atients with multifocal BAC were included in this study of
arly-stage lung cancer. At least one study demonstrated
ignificantly greater detectability of multifocal disease on
ET when compared with solitary BAC.19 We did not find
hat patients with multifocal BAC were more likely to have
DG-avid tumors, although we did not have enough pa-
ients with multifocal disease to detect a more subtle differ-
nce in FDG avidity. Although patients with multifocal
AC would be considered to have T4 or M1 disease by
urrent American Joint Committee on Cancer TNM staging,
atients with multifocal BAC who undergo complete sur-
ical resection have long-term survival comparable with
hat of patients with stage I disease.27,28
There are several limitations to this study. This is a
ingle-institution study, and other institutions should con-
rm our findings. Also, athough most patients were imaged
t our institution, several patients had PET scans at satellite
acilities that used a similar technique to perform the scans.
our patients were excluded because there was insufficient
nformation on tumor SUV and technique. Finally, patho-
ogic specimens were not re-reviewed for this study, al-
hough complete pathology reports were reviewed to ensure
roper assignment of diagnosis. Although it would have
een ideal to review the pathology of all our patients with
AC and adenocarcinoma, our results are arguably more
eneralizable to clinical practice.
The molecular basis for the unique biology of tumors
ith BAC histology is not well understood and more inves-
igation is needed into the molecular predictors of survival
n BAC. Until molecular markers of prognosis are identified
nd sufficiently validated for clinical use, tumor FDG avid-
ty seems to be a reasonable surrogate marker of lung cancer
ggressiveness. Among patients with BAC who undergo
omplete surgical resection, FDG-PET appears to be a pow-
rful prognostic test to identify patients at high and low risk
f mortality.
We thank David Glidden, PhD, from the Department of Bio-
tatistics and Epidemiology for assistance with statistics. These
tudies were carried out in part with the support of staff at the
eneral Clinical Research Center, Moffitt/MZ Hospital, Univer-
ity of California, San Francisco.
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